ASH 2021 | CAR T-cell therapy: the importance of donor-derived cells in treatment
In this video, Chiara Magnani, PhD, University of Milano-Bicocca, Milan, Italy & Fondazione MBBM, Monza, Italy, discusses the complexities associated with CAR-T cell products and the importance of allogeneicity in donor-derived T-cells when treating patients. First, Dr Magnani briefly explains the high cost associated with using viral vectors to produce CAR-T cells, and the benefit that sleeping beauty (SB) can offer in reducing costs. Following this, Dr Magnani shares her insights into the challenges faced with patients who are unable to enrol in CAR-T cell trials for various reasons. She also explains the importance of using donor-derived cells in the future to provide better opportunities for these patients, and how allogeneicity and rejection play an important role. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
